- The recently implemented GAIN Act is expected to lure
companies back into R&D as well as attract new participants,
finds Frost & Sullivan
LONDON, March 31, 2015 /PRNewswire/ -- The growing threat
posed by multi-drug resistant gram-negative organisms
(MDR-GNBs) is lending a sense of urgency to the development
of antibacterial drugs worldwide. Upcoming regulatory reforms to
lower R&D costs and provide incentives for new drug
identification will create attractive opportunities for
pharmaceutical manufacturers.
Logo - http://photos.prnewswire.com/prnh/20150331/195565LOGO
New analysis from Frost & Sullivan, A Product and
Pipeline Analysis of the Antibacterial Drugs Market, finds that
nearly 80 percent of drugs currently in the pipeline are
from smaller pharmaceutical and biotech companies, of which half do
not have any commercialized products in the market.
GlaxoSmithKline (www.gsk.com), AstraZeneca
(www.astrazeneca.com) and Merck & Co (www.merck.com) are
the only three established pharmaceutical organizations in the
antibacterial drug space.
For complimentary access to more information on this research,
please visit:
http://corpcom.frost.com/forms/EU_PR_AZanchi_MABA-52_20Mar15.
"Thirty eight antibacterial drugs currently under development
have the potential to address many, but not all, resistant
bacteria," said Frost & Sullivan Healthcare Senior Research
Analyst Aiswariya Chidambaram. "Plazomicin and
Eravacycline are two emerging compounds that have a
broad-spectrum activity against most MDR-GNBs."
Discovering new antibacterial drugs and identifying novel
compounds that can successfully target bacteria is scientifically
challenging. Given the high probability of failure and steep
research and development (R&D) costs, big pharma
companies that were once leaders are closing down their
antibacterial research facilities.
Agencies such as the Food and Drug Administration (FDA)
and the Infectious Diseases Society of America are deploying
several initiatives to lure companies back into antibacterial
R&D. The recently implemented Generating Antibiotic Incentives
Now (GAIN) Act is expected to facilitate more efficient
clinical studies and reduce barriers to market entry. In
Europe, the Innovative Medicines
Initiative (IMI) has launched two projects – Combatting
Bacterial Resistance in Europe
(COMBACTE) and TRANSLOCATION (molecular basis of the bacterial cell
wall permeability) – that showcase an unprecedented partnership
between industry, biotech organizations, and academia to fight
antibiotic resistance.
"Further, collaborations in the form of public-private
partnerships among industry, academia, investors and key
opinion leaders will effectively address the vast unmet clinical
and commercial needs in the antibacterial drugs market and quicken
the journey towards commercialization," concluded Chidambaram.
A Product and Pipeline Analysis of the Antibacterial Drugs
Market is part of the Life Sciences Growth Partnership
Service program. Frost & Sullivan's related studies include: A
Competitive Analysis of the Global Breast Cancer Therapeutics
Market, A Product and Pipeline Analysis of the Opioid Therapeutics
and Drug Delivery Market, A Product and Pipeline Analysis of the
Lung Cancer Therapeutics Market, and Product and Pipeline Analysis
of the Global Rheumatoid Arthritis Therapeutics Market. All studies
included in subscriptions provide detailed market opportunities and
industry trends evaluated following extensive interviews with
market participants.
About Frost & Sullivan
Frost & Sullivan, the
Growth Partnership Company, works in collaboration with clients to
leverage visionary innovation that addresses the global challenges
and related growth opportunities that will make or break today's
market participants. For more than 50 years, we have been
developing growth strategies for the global 1000, emerging
businesses, the public sector and the investment community. Is your
organization prepared for the next profound wave of industry
convergence, disruptive technologies, increasing competitive
intensity, Mega Trends, breakthrough best practices, changing
customer dynamics and emerging economies?
Contact
Anna
Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com